Momenta Pharmaceuticals, Inc. (MNTA)

[10nisman]

SNY's Q4 results are out...

http://en.sanofi-aventis.com/binaries/20110109_RESULTS2010_en_tcm28-30324.pdf

Lovenox® net sales in the fourth quarter were €582 million, down 26.9% and were impacted by a generic competitor in the U.S. (U.S. sales were €233 million down 51.7%). Outside the U.S., Lovenox® sales reached €349 million (representing 60.0% of Lovenox sales in the fourth quarter), an increase of 8.4%. Full year 2010 net sales of Lovenox® reached €2,806 million (-10.5%), 48.7% of which was generated outside the U.S. (€1,367 million, up 7.8%).